Immutep Moves Forward with Breakthrough Trial of IMP761
Immutep Making Significant Progress with IMP761 Trial
Media Release
First safety data anticipated before year-end with PK/PD assessments to follow.
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a cutting-edge biotechnology firm, is excited to announce that its Phase I clinical trial of IMP761 has reached a pivotal point. The initial phase of the study, designed to evaluate this innovative LAG-3 immunotherapy, is now fully recruited, and participants have begun receiving the medication without reported safety issues.
From Single Doses to Escalating Findings
The trial, taking place at the Centre for Human Drug Research (CHDR) in the Netherlands, has passed the first stage and is now entering the dose escalation segment. This stage involves administering escalating doses of IMP761 starting at 0.03 mg/kg and potentially reaching up to 0.90 mg/kg for 30 healthy volunteers. The primary focus here will be on both safety and pharmacokinetic (PK) as well as pharmacodynamic (PD) analyses.
Anticipating Enthusiastic Results
As the trial progresses, CHDR will utilize a special model known as the keyhole limpet haemocyanin (KLH) challenge in order to assess the pharmacodynamic activity of IMP761 at this early but critical phase of development. Immutep is optimistic about sharing initial safety data by the end of the year, with further detailed insights regarding PK/PD relationships expected in the first half of the next calendar year.
The Promise of IMP761
IMP761 is a unique first-in-class immunosuppressive LAG-3 agonist antibody, which targets the fundamental causes of various autoimmune diseases. By specifically suppressing memory T cells that accumulate in inflamed tissues, this therapy hopes to restore balance in the immune system.
Exciting Preclinical Findings
Recent preclinical studies highlight the potential of IMP761 to inhibit crucial responses in T cell proliferation and activation, showcasing its promise in managing conditions like oligoarticular juvenile idiopathic arthritis (o-JIA). Results published in notable journals have demonstrated that IMP761 significantly reduces inflammatory responses in just 48 hours for patients suffering from o-JIA, suggesting children with altered LAG-3 metabolism may greatly benefit from this therapy.
About Immutep and Its Vision
Immutep is at the forefront of biotechnology, specializing in the development of innovative therapies centered around LAG-3 mechanisms, aiming to treat both cancer and autoimmune diseases. With a diverse portfolio, the company is committed to advancing treatment options while also maximizing value for its shareholders.
Dedicated Support for Investors and Media
For further inquiries regarding this trial or for media engagement, investors and media representatives are urged to reach out to the respective contacts provided by Immutep. This includes representatives in both Australia and the U.S., who are dedicated to facilitating clear and informative communication regarding ongoing developments.
Frequently Asked Questions
What is the focus of Immutep's IMP761 study?
The study focuses on evaluating IMP761's safety and its pharmacokinetic and pharmacodynamic properties in healthy volunteers.
How does IMP761 work?
IMP761 is designed to suppress autoimmune memory T cells to help restore balance to the immune system, targeting the underlying causes of autoimmune diseases.
What results is Immutep expecting in the trial?
Immutep anticipates the first safety data to be available before the year ends and further PK/PD assessments in the first half of the following year.
Who is leading the clinical trial?
The trial is being conducted by the Centre for Human Drug Research (CHDR) in the Netherlands.
How can I find more information about Immutep?
For more details about Immutep and its ongoing trials, interested parties can visit the official website of Immutep.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Foundation Source Strengthens Portfolio with Vennfi Acquisition
- U.S. Postal Service Enhances Election Mail with New Video Tips
- CBRE Group Inc Reaches New Heights with Stock Surge
- DaVita Welcomes Jessica Hergenreter as Chief People Officer
- Revolutionizing Farming: The Impact of Untether AI's Solutions
- Viant Technology Boosts Growth with New AI Tool Strategy
- Celebrating Heroes: New Inductees in Blood Donation Hall of Fame
- Phillip Sarofim Joins National Air and Space Museum Board
- BloFin Partners with Fireblocks to Elevate Cold Wallet Security
- Inszone Insurance Services Expands with Anixter & Oser Deal
Recent Articles
- Mobix Labs Achieves Impressive Growth and Expands Market Reach
- US Power Demand Surge: Utilities Brace for Transformative Changes
- B. Riley Modifies Price Target Following GM and Lithium Deal
- Sunnova's Remarkable Resilience Amid Hurricanes Milton and Helene
- Exploring the Future of Cold Plasma Market: Insights and Growth
- Alcoa's Strong Performance Fuels Upgrade and Growth Prospects
- Growing Demand for Fitness Equipment: Market Insights Ahead
- Eric Murphy of Alterome Celebrated as Goldman Sachs Entrepreneur
- TSMC Sets a High Bar as Chipmakers Soar Amid Market Shifts
- CSX Sees Decline Amid Sluggish Q3 Results and Outlook
- Exploring the Rapid Expansion of Surgical Robots Market Growth
- New Digital Leadership at Avnet: Dave Youngblood's Impact
- Eco-Friendly Molded Pulp Packaging Market Growth Insights
- Broadcom's Promising Future: What Investors Should Know Now
- Jüsto Raises $70 Million to Transform Grocery Shopping in LATAM
- Antiseptic and Disinfectant Market Growth and Projections
- Exploring Promising AI Investments Ahead of Earnings Reports
- Understanding Challenges in the Individual Annuity Market
- LyondellBasell Enhances Sustainability with APK Acquisition
- ShiftPixy Enhances AI Capabilities with TurboScale Acquisition
- Windtree Boosts Heart Failure Treatment with New Patent in Japan
- Piper Sandler Prepares to Unveil Q3 2024 Financial Insights
- Sienna Secures $150 Million Through Senior Unsecured Debentures
- WisdomTree Unveils Innovative Say Platform Ahead of Q3 Call
- Lightbridge Corporation's Upcoming Financial Conference Call
- Hydrofarm Leader Transition: A New Era for Hydroponics Company
- Morgan Stanley Survey Shows Investor Confidence Amid Challenges
- Worksport Shows Strong Commitment to Financial Efficiency Ahead of Launches
- Redfin's Home Sales Increased Despite Rising Mortgage Rates
- Eterna Therapeutics Expands Collaboration with Factor Bioscience
- Yamaha's Hydrogen Innovations Set to Transform Marine Industry
- Exploring the Rise of Rent Payment Reporting among Managers
- Industrial Giants Announce Impressive Dividend Increases
- Doman Building Materials Group Reveals Q3 2024 Financial Results
- CoinFlip Expands Digital Currency Access Across Convenience Stores
- Exploring Ardelyx's Upcoming Financial Insights and Developments
- Unlocking Your Social Security Benefits for a Secure Retirement
- Clarion Partners Real Estate Income Fund Shares Tender Results
- ProPhase Labs Sets Stage for Growth with Key Strategic Moves
- Blackstone's Record Growth: A Closer Look at Its Success
- Eliah Kahn Joins Patra as New Managing Director to Drive Growth
- Phunware Showcases Innovative Mobile Solutions at Major Event
- Total Energy Services Inc. Initiates Share Buyback Plan
- Chaparral and Robalo Boats Partner with Yamaha for Financing
- Alico, Inc. Reports Minimal Impact from Hurricane Milton
- Transforming Grocery Shopping: Local Express Partners Swiftly
- Intra-Cellular Therapies Set for Financial Results Call
- TSG Consumer Partners Welcomes Brian Crandall to Enhance Value Creation
- SAIHEAT's Strategic MoU to Propel Nuclear Market Leadership
- Houlihan Lokey Sets Conference for Second Quarter Financials